NR 293 RUA

Name

Chamberlain University

NR-293: Pharmacology for Nursing Practice

Prof. Name

Date

Medication Teaching Plan: Xtampza ER Oxycodone

Introduction

The focus of this medical teaching plan brochure is Xtampza ER Oxycodone, a narcotic analgesic. Oxycodone is primarily intended for individuals experiencing pain. It functions by binding to opiate receptors in the central nervous system (CNS), altering both the perception and response to painful stimuli while inducing generalized CNS depression (Vallerand, Sanoski, & Quiring, 2019). The therapeutic goal of oxycodone is to reduce pain levels effectively. Pediatric patients may also be prescribed oxycodone at lower doses, specifically 0.05–0.15 mg/kg every 4–6 hours as needed (Vallerand, Sanoski, & Quiring, 2019). This brochure aims to inform users about the medication’s details, including drug classification, mechanism of action, administration and dosage guidelines, potential drug interactions, laboratory effects or interference, special considerations, adverse effects or toxicity, patient assessments, and essential patient education.

Patient Education

An essential component of patient education is to ensure that individuals are informed about the timing, route, and dosage of oxycodone. Without proper information, patients may encounter significant issues related to their medication. A primary concern regarding the use of oxycodone is its potential for abuse. It is crucial to advise patients about this risk, emphasizing that oxycodone has known abuse potential. Patients should be instructed to secure their medication from theft and never to share it with others. Additionally, oxycodone should be stored out of reach of children and in a location not easily accessible to others (Vallerand, Sanoski, & Quiring, 2019). Educating patients about drug abuse and how to prevent it is a vital aspect of patient teaching. Furthermore, the resource detailing Xtampza ER oxycodone capsules indicates that the medication may cause fetal harm and should be avoided during pregnancy.

Conclusion

In summary, the oxycodone brochure is designed to provide essential information in an accessible format for non-medical individuals. This resource is intended to equip patients and their families with the knowledge needed to use the medication safely and effectively. Ensuring that patients are well-informed about oxycodone’s properties and the importance of responsible use will contribute to improved patient outcomes and minimize the risk of abuse.

References

Collegium Pharmaceutical, Inc. (n.d.). XTAMPZA ER- oxycodone capsule, extended release. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c

NR 293 RUA

Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2019). Davis’s drug guide for nurses. F. A. Davis Company.